Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xingya Li

Showing results (61-70 of 146) with videos related to

Pageof 15
Sort By:
Oncology and Therapy|September 14, 2025
First-Line Tislelizumab Plus Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer: PD-L1 ≥ 50% Subgroup Analysis from the RATIONALE-304 TrialShun Lu, Jie Wang, Yan Yu, et al.
The Lancet. Respiratory Medicine|July 7, 2026
Ifebemtinib plus garsorasib as first-line treatment for KRAS<sup>G12C</sup>-mutated non-small-cell lung cancer in China: a multicentre, single-arm expansion cohort from a phase 1b/2 trialZhengbo Song, Xingya Li, Rongbo Lin, et al.
Journal of the American Chemical Society|May 19, 2022
Highly Ion-Permselective Porous Organic Cage Membranes with Hierarchical ChannelsTingting Xu, Bin Wu, Linxiao Hou, et al.
Nature Communications|January 18, 2023
Construction of angstrom-scale ion channels with versatile pore configurations and sizes by metal-organic frameworksXingya Li, Gengping Jiang, Meipeng Jian, et al.
Scientific Reports|February 13, 2024
A pivotal bridging study of lurbinectedin as second-line therapy in Chinese patients with small cell lung cancerYing Cheng, Chunjiao Wu, Lin Wu, et al.
Lung Cancer (Amsterdam, Netherlands)|September 5, 2022
Rare EGFR E709-T710delinsX: Molecular characteristics and superior response to afatinib treatment in NSCLC patientsYihua Huang, Chunwei Xu, Yuanliang Sun, et al.
Advanced Materials (Deerfield Beach, Fla.)|May 12, 2020
Unidirectional and Selective Proton Transport in Artificial Heterostructured Nanochannels with Nano-to-Subnano Confined Water ClustersXingya Li, Huacheng Zhang, Hao Yu, et al.
BMC Medicine|January 8, 2023
Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa studyYuankai Shi, Jianying Zhou, Yanqiu Zhao, et al.
Nature Communications|September 24, 2025
Multifunctional intercalants create stable subnanochannels in MoS<sub>2</sub> membranes for wastewater treatmentHao Zhang, Ming Yong, Ting Hu, et al.
European Journal of Cancer (Oxford, England : 1990)|July 2, 2023
Efficacy and safety of KN046, a novel bispecific antibody against PD-L1 and CTLA-4, in patients with non-small cell lung cancer who failed platinum-based chemotherapy: a phase II studyAnwen Xiong, Wei Li, Xingya Li, et al.
Pageof 15

Showing results (61-70 of 146) with videos related to

Sort By:
Pageof 15
Oncology and Therapy|September 14, 2025
First-Line Tislelizumab Plus Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer: PD-L1 ≥ 50% Subgroup Analysis from the RATIONALE-304 TrialShun Lu, Jie Wang, Yan Yu, et al.
The Lancet. Respiratory Medicine|July 7, 2026
Ifebemtinib plus garsorasib as first-line treatment for KRAS<sup>G12C</sup>-mutated non-small-cell lung cancer in China: a multicentre, single-arm expansion cohort from a phase 1b/2 trialZhengbo Song, Xingya Li, Rongbo Lin, et al.
Journal of the American Chemical Society|May 19, 2022
Highly Ion-Permselective Porous Organic Cage Membranes with Hierarchical ChannelsTingting Xu, Bin Wu, Linxiao Hou, et al.
Nature Communications|January 18, 2023
Construction of angstrom-scale ion channels with versatile pore configurations and sizes by metal-organic frameworksXingya Li, Gengping Jiang, Meipeng Jian, et al.
Scientific Reports|February 13, 2024
A pivotal bridging study of lurbinectedin as second-line therapy in Chinese patients with small cell lung cancerYing Cheng, Chunjiao Wu, Lin Wu, et al.
Lung Cancer (Amsterdam, Netherlands)|September 5, 2022
Rare EGFR E709-T710delinsX: Molecular characteristics and superior response to afatinib treatment in NSCLC patientsYihua Huang, Chunwei Xu, Yuanliang Sun, et al.
Advanced Materials (Deerfield Beach, Fla.)|May 12, 2020
Unidirectional and Selective Proton Transport in Artificial Heterostructured Nanochannels with Nano-to-Subnano Confined Water ClustersXingya Li, Huacheng Zhang, Hao Yu, et al.
BMC Medicine|January 8, 2023
Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa studyYuankai Shi, Jianying Zhou, Yanqiu Zhao, et al.
Nature Communications|September 24, 2025
Multifunctional intercalants create stable subnanochannels in MoS<sub>2</sub> membranes for wastewater treatmentHao Zhang, Ming Yong, Ting Hu, et al.
European Journal of Cancer (Oxford, England : 1990)|July 2, 2023
Efficacy and safety of KN046, a novel bispecific antibody against PD-L1 and CTLA-4, in patients with non-small cell lung cancer who failed platinum-based chemotherapy: a phase II studyAnwen Xiong, Wei Li, Xingya Li, et al.
Pageof 15